Cognetivity Neuroscience (CSE: CGN) this morning indicated that it continues to see adoption of its Integrated Cognitive Assessment, also known as ICA. The firm has partnered with the UK’s National Health Service to implemented the assessment as part of a new clinic focused on early-stage dementia diagnosis.
Referred to as a remote brain health clinic, the clinic is to be established at the South London and Maudsley NHS Foundation Trust, which is more commonly known as SLaM. The clinic is focused on identifying mild cognitive impairment and providing continuous remote assessment of patients that are suspected to develop Alzheimer’s disease.
The clinic is set to implement the firms Integrated Cognitive Assessment to support the early diagnosis of early-stage cognitive impairment. With the technology having the ability to be used remotely, the tech is to play a key role in the focus of the clinic, given that the assessment is computerized and has been found to work excellently remotely without the loss of testing accuracy in a peer reviewed study.
“We’re thrilled to see the ICA deployed as part of this ground-breaking new clinic at one of the UK’s premier mental health trusts. Early-stage diagnosis, facilitated by remote cognitive assessment and monitoring – this is the bright future of dementia medicine, without a doubt, and we’re delighted to be a part of it.”
Dr Sina Habibi, Cognetivity’s CEO
The launch of the clinic follows a recent emphasis being placed on Alzheimer’s by healthcare systems globally. Early stage interventions in the disease are currently known to be significantly more effective before the disease develops further, and the recent approval by the FDA of the drug aducanumab, while somewhat controversial, is expected to drive a further focus on dementia as a whole globally.
Cognetivity Neuroscience last traded at $1.02 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
